The adjuvant treatment revolution for high-risk melanoma patients
- PMID: 31445219
- DOI: 10.1016/j.semcancer.2019.08.024
The adjuvant treatment revolution for high-risk melanoma patients
Abstract
The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.
Keywords: Adjuvant; Immunotherapy; Melanoma; Neoadjuvant; Targeted therapy.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15. Recent Results Cancer Res. 2000. PMID: 10857171 Review.
-
Neoadjuvant Immunotherapy for Locally Advanced Melanoma.Curr Treat Options Oncol. 2020 Feb 5;21(2):10. doi: 10.1007/s11864-020-0700-z. Curr Treat Options Oncol. 2020. PMID: 32025932 Review.
-
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.Am J Clin Dermatol. 2019 Dec;20(6):817-827. doi: 10.1007/s40257-019-00456-4. Am J Clin Dermatol. 2019. PMID: 31177507 Review.
-
Uncertainties in the management of melanoma nodal metastasis.Eur J Surg Oncol. 2015 Jul;41(7):811-3. doi: 10.1016/j.ejso.2015.04.011. Epub 2015 Apr 30. Eur J Surg Oncol. 2015. PMID: 25980747 No abstract available.
-
The impact of the immunotherapy revolution on lymph nodal surgery.Bull Cancer. 2020 Jun;107(6):640-641. doi: 10.1016/j.bulcan.2019.05.013. Epub 2019 Oct 11. Bull Cancer. 2020. PMID: 31610910 No abstract available.
Cited by
-
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.Front Immunol. 2020 Jun 5;11:1147. doi: 10.3389/fimmu.2020.01147. eCollection 2020. Front Immunol. 2020. PMID: 32582212 Free PMC article. Clinical Trial.
-
Ca2+ overload- and ROS-associated mitochondrial dysfunction contributes to δ-tocotrienol-mediated paraptosis in melanoma cells.Apoptosis. 2021 Jun;26(5-6):277-292. doi: 10.1007/s10495-021-01668-y. Epub 2021 Apr 3. Apoptosis. 2021. PMID: 33811561 Free PMC article.
-
Current State of Target Treatment in BRAF Mutated Melanoma.Front Mol Biosci. 2020 Jul 14;7:154. doi: 10.3389/fmolb.2020.00154. eCollection 2020. Front Mol Biosci. 2020. PMID: 32760738 Free PMC article. Review.
-
Immune checkpoint inhibitors for the treatment of melanoma.Expert Opin Biol Ther. 2022 May;22(5):563-576. doi: 10.1080/14712598.2022.2038132. Epub 2022 Feb 13. Expert Opin Biol Ther. 2022. PMID: 35130816 Free PMC article. Review.
-
The Evolution of the Sentinel Node Biopsy in Melanoma.Life (Basel). 2023 Feb 10;13(2):489. doi: 10.3390/life13020489. Life (Basel). 2023. PMID: 36836846 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
